Home › Research › Treatments
Clinical, neuroimaging, and biomarker profiling of four Alzheimer's disease pedigrees caused by pathogenic APP variants
Zhang JW, Li R, Niu YX, Liu SY, Li CH, Hao XD, Wang SH, Chen S et al.. Alzheimer's research & therapy, 2026-03-19
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Based on family informant reports and clinical observations, the median age at onset (AAO) among affected individuals in these pedigrees was 48.50 (44.0, 51.8) years. Plasma biomarker analyses showed that P-tau181, P-tau217, and GFAP levels were significantly higher in the SMC and SAD groups than in the AMC and NC groups (P_FDR < 0.05). Compared with the SMC group, the SAD group exhibited higher Aβ40 levels and a lower Aβ42/Aβ40 ratio (P_FDR < 0.05). Among V717I carriers, multiple biomarkers differed significantly between SMC and AMC (P_FDR < 0.05), whereas no significant differences were detected in the D678G or M722K subgroups. In addition, given the current sample size, APOE ε4 status was not associated with additional modification of plasma biomarker levels or AAO. No amyloid-related imaging abnormalities (ARIA) were observed during the lecanemab treatment period. From the pre-infusion baseline to immediately before the 15th infusion, one patient showed decreases in P-tau181 (− 5.70%), P-tau217 (− 12.23%), and GFAP (− 42.93%), accompanied by a mild improvement in cognitive performance; the other patient showed a reduction in P-tau181 (− 28.30%) but increases in GFAP (+ 36.59%) and NfL (+ 174.01%), with overall stable cognition. Plasma biomarkers provide critical evidence to advance our understanding of APP variant-associated EOAD. Both APP variant-associated EOAD and sporadic EOAD showed a similar biomarker profile, with higher plasma P-tau181, P-tau217, and GFAP levels than those in AMC and NC. In contrast, the two groups exhibited divergent patterns in Aβ40 levels and the Aβ42/Aβ40 ratio. In addition, given the current sample size, APOE ε4 status was not found to have an additional modifying effect on plasma biomarkers among APP variant carriers.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, J. W., Li, R., Niu, Y. X., Liu, S. Y., Li, C. H., Hao, X. D., et al. (2026). Clinical, neuroimaging, and biomarker profiling of four Alzheimer's disease pedigrees caused by pathogenic APP variants. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-026-02016-5
Vancouver
Zhang JW, Li R, Niu YX, Liu SY, Li CH, Hao XD, et al. Clinical, neuroimaging, and biomarker profiling of four Alzheimer's disease pedigrees caused by pathogenic APP variants. Alzheimer's research & therapy. 2026. doi:10.1186/s13195-026-02016-5. PMID: 41851792.
BibTeX
@article{zhang2026-41851792,
author = {Zhang, J. W. and Li, R. and Niu, Y. X. and Liu, S. Y. and Li, C. H. and Hao, X. D. and Wang, S. H. and Chen, S. and others},
title = {{Clinical, neuroimaging, and biomarker profiling of four Alzheimer's disease pedigrees caused by pathogenic APP variants}},
journal = {Alzheimer's research \& therapy},
year = {2026},
doi = {10.1186/s13195-026-02016-5},
pmid = {41851792},
url = {https://doi.org/10.1186/s13195-026-02016-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Based on family informant reports and clinical observations, the median age at onset (AAO) among affected individuals in these pedigrees was 48.50 (44.0, 51.8) years.
- Plasma biomarker analyses showed that P-tau181, P-tau217, and GFAP levels were significantly higher in the SMC and SAD groups than in the AMC and NC groups (P_FDR < 0.05).
- Compared with the SMC group, the SAD group exhibited higher Aβ40 levels and a lower Aβ42/Aβ40 ratio (P_FDR < 0.05).
- Among V717I carriers, multiple biomarkers differed significantly between SMC and AMC (P_FDR < 0.05), whereas no significant differences were detected in the D678G or M722K subgroups.
- In addition, given the current sample size, APOE ε4 status was not associated with additional modification of plasma biomarker levels or AAO.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Participants206
- Effect size5.70%; 12.23%; 42.93%
- Evidence strengthModerate
How this study scored 74/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 43 of the 58 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 206 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41851792) |
| Free to read | 2 / 2 | Free to read |
| Points | 43 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 58 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “four”
3 studies in the library carry the topic tag “four”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 3 tagged studies.